• Important Safety Information
  • For Healthcare Professionals
  • Contact Us
  • Email this page
  • AAA Text Size

Financial Support


If you need a hand paying for your treatments, we can help. Pfizer has a financial support program available and can connect you to other assistance programs:

  • SOMAVERT Copay/Coinsurance Support Program®*
  • Other sources of financial assistance
Asc Card

SOMAVERT Copay/Coinsurance Support Program

  • Pfizer offers privately insured patients access to the SOMAVERT Copay/Coinsurance Support Program
  • Now patients with private insurance can pay just $5 a month for their prescription—the SOMAVERT Copay/Coinsurance Support Program pays the rest, up to $5000 per year!
  • Call 1-800-645-1280 to sign up or for more information
  • There are no financial restrictions for this program*

Other Sources of Financial Assistance

In addition, the Pfizer Bridge Program may help you find other sources of financial support provided by third-party organizations when funding is available. For more information, call the Pfizer Bridge Program at 1-800-645-1280.

Next: SOMAVERT Treatment Support >>

*By using the SOMAVERT® Copay/Coinsurance Support Program Card (the “Card”), patients acknowledge that they currently meet the eligibility criteria and will comply with the terms and conditions described below:

The Card is not valid for:

  • prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or other federal or state healthcare programs
  • prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs which reimburse patients for the entire cost of their prescription drugs

The Card covers copay/coinsurance costs up to $5000 for a period of 12 months; actual level of assistance will be determined by the Pfizer Bridge Program®. Patients are responsible for a $5 monthly copayment based upon program utilization. Patients must deduct the value received under this program from any reimbursement request submitted to the patient’s insurance plan, either directly by the patient or on the patient’s behalf.

The Card is not valid in Puerto Rico.

This program cannot be combined with any other rebate/coupon, free trial or similar offer for the specified prescription.

The Card will be accepted only at participating pharmacies. The Card is not health insurance. No membership fees.

Offer good only in the U.S. The Card is limited to 1 per person during this offering period and is not transferable. Pfizer reserves the right to rescind, revoke or amend this offer without notice. Card and Program expire on the patient’s eligibility end date. For more information, please call 1-800-645-1280 or visit Pfizer.com.

Pfizer Inc, 235 East 42nd Street, New York, NY 10017.

Your SOMAVERT Starter Kit

As you begin treatment, your starter kit includes several tools that you may find helpful


SOMAVERT (pegvisomant for injection) is a prescription medicine for acromegaly. It is for patients whose disease has not been controlled by surgery, radiation, and/or other medical therapies, or patients for whom these options are not appropriate. The goal of treatment with SOMAVERT is to have a normal IGF-I level in the blood.

Important Safety Information for Patients

Do not use SOMAVERT if you are allergic to SOMAVERT or anything that is in it.

Be sure to tell your doctor if you use narcotic painkillers (opioid medicines) because the dose of SOMAVERT may need to be changed.

Tumors that make growth hormone may grow in people with acromegaly. Studies have shown that the size of these tumors generally does not change for people who use SOMAVERT. Even so, these tumors need to be watched carefully by your doctor. Your doctor may ask you to have a magnetic resonance imaging (MRI) test to monitor the size of your tumor.

Blood sugar levels may go down when taking SOMAVERT. Be sure to tell your doctor if you use insulin or other medicines (oral hypoglycemic medicines) for diabetes. The dose of these medicines may need to be reduced when you use SOMAVERT.

Some people who have used SOMAVERT have developed liver problems. These problems generally disappeared when those people stopped taking SOMAVERT.

Stop the drug right away and call your doctor if you get any of these symptoms:

  • Your skin or the white part of your eyes turns yellow (jaundice)
  • Your urine turns dark
  • Your bowel movements (stools) turn light in color
  • You do not feel like eating for several days
  • You feel sick to your stomach (nausea)
  • You have unexplained tiredness
  • You have pain in the stomach area (abdomen)

Your doctor may do blood tests before and during your treatment with SOMAVERT to check that the IGF-I levels in your blood are normal and/or that your liver is working correctly. Your dose of SOMAVERT may be changed based on the results of these tests.

If you have stopped SOMAVERT because of an allergic reaction, your doctor will carefully monitor what happens if you start SOMAVERT again.

The most common side effects with SOMAVERT are pain, infection, reaction at the injection site, flu-like symptoms, nausea, and diarrhea. These are not all of the possible side effects of SOMAVERT. For more information, speak to your doctor.

Inject SOMAVERT in a different place on your body each day. This can help prevent skin problems such as lumpiness or soreness.

SOMAVERT has not been studied in pregnant women. It is not known if SOMAVERT passes into the mother’s milk or if it can harm the baby.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

This product information is intended only for residents of the United States and Puerto Rico. The products discussed herein may have different labeling in different countries.



SMU545302-01